Clinical Trial

Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Study acronym: INO&MS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS. The objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion. The study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-24.
Trial Details
NCT Number NCT07560995
Lead Sponsor University Hospital, Strasbourg, France
Conditions Multiple Sclerosis, Internuclear Ophthalmoplegia
Enrollment 200 participants
Start Date 2026-05
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-08